Ibrutinib is a kind of tyrosine kinase inhibitor that targets Bruton’s tyrosine kinase (BTK), specifically. It’s mainly used to treat different types of lymphomas like mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenström’s macroglobulinemia. The drug works by blocking BTK signaling, which stops cancer cell growth and keeps them from surviving.
Ibrutinib comes as 140 mg capsules or tablets, and they usually suggest taking between 420 to 560 mg of it once a day. The med comes in bottles, each holding 90 tablets.
